GI Innovation outlined ambitious plans to transfer at least five additional technologies within the next five years at its initial public offering (IPO) briefing session at the Conrad Hotel in Yeouido, Seoul, Monday.Established as a bio-venture in 2017, GI Innovation researches and develops next-generation immunotherapy drugs based on dual fusion proteins. The company's major pipelines include dual fusion immuno-cancer drugs GI-101 and GI-102, and allergy treatment GI-301 which are in clinical trials alongside other preclinical drug candidates GI-104, GI-108, and GI-305.https://www.koreabiomed.com/news/articleView.html?idxno=20640

GI Innovation said Thursday that it has won approval in the preliminary screening to be listed on the Kosdaq market from the Korea Exchange (KRX). The approval came eight months after the company applied for a preliminary review in April. Read More

Preliminary results of GII-101-P101 (Keynote-B59): GI-101 (CD80-IgG4 Fc-IL2v) as a single agent and in combination with pembrolizumab in patients with advanced and/or metastatic solid tumors

Local drug developer GI Innovation said Thursday its Merkel cell cancer drug GI-101, used to treat a rare type of skin cancer, has received orphan drug designation from the United States Food and Drug Administration.The designation is given to drugs that treat rare diseases that affect less than 100,000 people. The status gives tax cuts during clinical trials, and waives certain restrictions and fees. It also allows market monopolization for seven years after the drug is launched.Merkel cell cancer appears between the dermis and epidermis of the skin and mostly affects those over 50. The five-year survival rate is less than 20 percent.GI Innovation said it hopes the designation will accelerate clinical trials for its Merkel cell cancer drug. Read More

SEOUL -- A material patent for GI-301, an allergy treatment drug candidate developed by South Korea's bio-venture company GI Innovation, has been registered in Japan where pollen allergy diseases are widespread. The company would try to accelerate technology transfer to Japanese pharmaceutical companies.GI-301 is a biologic for the treatment of allergic diseases, including atopic dermatitis and chronic idiopathic. Yuhan, a pharmaceutical and chemical company in South Korea, signed a contract worth some 20 billion won ($15 million) in 2020 to co-develop and sell GI-301 in overseas markets except for Japan. Read More

GI-101, an immunotherapy agent being developed by South Korea's bio-venture company GI Innovation, has been selected for a government-initiated drug development program to receive financial support at clinical stages. GI Innovation said it would get up to seven billion won ($5.5 million) in research support for two years from the Korea Drug Development Fund (KDDF), which supports the investment, nurture and development of promising drugs. KDDF's move is seen as a symbolic recognition of GI Innovation's technological prowess. Read More

Local drug developer GI Innovation has submitted a preliminary application for listing on the country’s secondary tech-heavy bourse Kosdaq with its eyes set on going public in the second half of the year, the company said Thursday.GI Innovation’s initial public offering will be carried out under Kosdaq’s special listing track, known as the “unicorn special listing.”The Korea Exchange established the unicorn special listing process in April last year to simplify the technological evaluation process for companies with excellent market evaluation. Read More

GI Innovation, an innovative new drug development company, announced on February 23 that it has signed a biomarker joint research MoU with CellKey, a Glycoprotein biomarker development company, to develop next-generation innovative immuno-oncology. GI Innovation signed MoU with CellKey for biomarker joint research to develop next-generation innovative immuno-oncology. (from left) Ji-Soo Kim director, Na-Ri Yun VP, Myoung-Ho Jang Chairman of GI Innovation and Nam-Yong Lee CEO, Sang-Yong Lee COO, Kwang-Hoe Kim Head of Bio-R&D center of CellKey participated in the MoU ceremony. Under the MoU, GI Innovation will progress joint biomarker research to develop next-generation protein and antibody drugs using GI Innovation’s bispecific fusion protein development platform GI-SMART™ and CellKey’s AI-powered biomarker discovery platform SpAC9 Pipeline. Read More

GI Innovation said it has entered into a partnership with GI Cell and Yonsei University Health System (YUHS) to establish a cell therapy center for advanced biopharmaceuticals.Under the accord, GI Innovation and GI Cell will increase the production capability of advanced biopharmaceuticals with YUHS by establishing good manufacturing practice (GMP) facilities in Severance Hospital and Songdo Severance Hospital under construction. Read More

GI Innovation said it has entered a clinical collaboration agreement with AstraZeneca to develop a combination therapy of GI-101 and Imfinzi. Under the accord, GI Innovation and AstraZeneca will conduct clinical trials assessing a combination regimen between GI-101 and Imfinzi to treat small cell lung cancer, gastric and gastroesophageal junction cancer, biliary tract cancer, and triple-negative breast cancer in the U.S., Australia, and Korea.AstraZeneca will provide Imfinzi and expertise in developing immunotherapy for successful completion of clinical trials by co-designing and developing a plan for the clinical trials. Read More

Merck said it has signed a memorandum of understanding (MoU) with GI Innovation, a Korean bioventure company, to further R&D efforts on critical life-saving cancer treatments and drugs for allergy-related conditions.Under the accord, Merck will support GI Innovation with technologies and services, including the CHOZN platform, which improves the accuracy and efficiency in developing new drugs in the early stage, cell culture media, and overall process consulting and technical support, to help the latter develop immunotherapy and allergy treatments. Read More

South Korea's bio-venture company GI Innovation will cooperate with a domestic clinical development and research organization for the development and commercialization of candidate materials for next-generation immuno-cancer drugs.GI Innovation and Medirama will jointly develop two cases of immune-cancer drugs, including GI Innovations's new dual fusion protein, and share profits after commercialization. Read More